Skip to main content
SpringerLink
Log in

Mantle Cell Lymphoma

  • Chapter
  • First Online:
Novel Therapeutics for Rare Lymphomas

Abstract

Mantle cell lymphoma is an aggressive and rare type of non-Hodgkin’s lymphoma that is considered incurable. It is a heterogeneous disease with diverse clinical presentations and complex treatment courses. In this chapter, the presentation, diagnosis, and conventional treatment will be discussed and outlined for the frontline setting in both young fit adults and the elderly. This will be followed by an in-depth analysis regarding exciting novel therapies and combinations being investigated, from early stage development to ongoing clinical trials. We will finish with a recommended treatment algorithm for frontline and relapsed disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7(10):750–62.

    Article  CAS  PubMed  Google Scholar 

  2. Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113(4):791–8.

    Article  PubMed  Google Scholar 

  3. Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2017;181:703–6.

    Article  PubMed  Google Scholar 

  4. Swerdlow SH, Williams ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol. 2002;33(1):7–20.

    Article  CAS  PubMed  Google Scholar 

  5. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003;97(3):586–91.

    Article  PubMed  Google Scholar 

  6. Kim JH, Jung HW, Kang KJ, Min BH, Lee JH, Chang DK, et al. Endoscopic findings in mantle cell lymphoma with gastrointestinal tract involvement. Acta Haematol. 2012;127(3):129–34.

    Article  CAS  PubMed  Google Scholar 

  7. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70(4):1408–18.

    Article  CAS  PubMed  Google Scholar 

  9. Narurkar R, Alkayem M, Liu D. SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma. Biomark Res. 2016;4:6.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Cheah CY, George A, Gine E, Chiappella A, Kluin-Nelemans HC, Jurczak W, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European mantle cell lymphoma network. Ann Oncol. 2013;24(8):2119–23.

    Article  CAS  PubMed  Google Scholar 

  11. Chin CK, Cheah CY. How I treat patients with aggressive lymphoma at high risk of CNS relapse. Blood. 2017;130(7):867–74.

    Article  CAS  PubMed  Google Scholar 

  12. Karube K, Scarfo L, Campo E, Ghia P. Monoclonal B cell lymphocytosis and “in situ” lymphoma. Semin Cancer Biol. 2014;24:3–14.

    Article  CAS  PubMed  Google Scholar 

  13. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–65.

    Article  CAS  PubMed  Google Scholar 

  14. Geisler CH, Kolstad A, Laurell A, Raty R, Jerkeman M, Eriksson M, et al. The mantle cell lymphoma international prognostic index (MIPI) is superior to the international prognostic index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115(8):1530–3.

    Article  CAS  PubMed  Google Scholar 

  15. Eskelund CW, Kolstad A, Jerkeman M, Raty R, Laurell A, Eloranta S, et al. 15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410–8.

    Article  CAS  PubMed  Google Scholar 

  16. Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–10.

    Article  CAS  PubMed  Google Scholar 

  17. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209–13.

    Article  PubMed  Google Scholar 

  18. Cohen JB, Han X, Jemal A, Ward EM, Flowers CR. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer. 2016;122(15):2356–63.

    Article  CAS  PubMed  Google Scholar 

  19. Abrisqueta P, Scott DW, Slack GW, Steidl C, Mottok A, Gascoyne RD, et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017;28(10):2489–95.

    Article  CAS  PubMed  Google Scholar 

  20. Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European mantle cell lymphoma network. Lancet. 2016;388(10044):565–75.

    Article  CAS  PubMed  Google Scholar 

  21. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016;172(1):80–8.

    Article  CAS  PubMed  Google Scholar 

  22. Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG study S1106. Br J Haematol. 2017;176(5):759–69.

    Article  CAS  PubMed  Google Scholar 

  23. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood. 2005;105(7):2677–84.

    Article  CAS  PubMed  Google Scholar 

  24. Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250–60.

    Article  PubMed  Google Scholar 

  25. Lacout C, De Vries M, Seegers-Thepot V, Clavert A, Farhi J, Mercier M, et al. R-DHA-Oxaliplatin versus R-DHA-cisplatin regimen in B-cell Nhl’s treatment: a eight years retrospective study. Blood. 2015. American Society of Hematology;126(23):3959.

    Google Scholar 

  26. Lignon J, Sibon D, Madelaine I, Brice P, Franchi P, Briere J, et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10(4):262–9.

    Article  CAS  PubMed  Google Scholar 

  27. Le Gouill S, Thieblemont C, Oberic L, Bouabdallah K, Gyan E, Damaj G, et al. R-DHA-Oxaliplatin before autologous stem cell transplantation prolongs PFS and OS as compared to R-DHA-carboplatin and R-DHA-cisplatin in patients with mantle cell lymphoma, a subgroup analysis of the LyMa trial. Blood. 2017. American Society of Hematology;130(Suppl 1):1496.

    Google Scholar 

  28. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520–31.

    Article  CAS  PubMed  Google Scholar 

  29. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Rummel MJ, Knauf W, Goerner M, Soeling U, Lange E, Hertenstein B, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016;34(15):7503.

    Article  Google Scholar 

  31. Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31(11):1442–9.

    Article  CAS  PubMed  Google Scholar 

  32. Kahl BS, McGovern J, Blank J, Jaslowski A, Bayer G, Bottner WA, et al. Phase II study of modified hyper-CVAD with rituximab maintenance for previously untreated mantle cell lymphoma: a Wisconsin oncology network study. Blood. 2004. American Society of Hematology;104(11):1388.

    Article  Google Scholar 

  33. Chang JE, Carmichael LL, Kim K, Peterson C, Yang DT, Traynor AM, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin oncology network study. Clin Lymphoma Myeloma Leuk. 2018;18(1):e61–7.

    Article  PubMed  Google Scholar 

  34. Wang ML, Lee H, Thirumurthi S, Chuang H, Hagemeister F, Westin J, et al. Ibrutinib rituximab followed by reduced chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma patients: a window of opportunity to reduce chemo. Hematol Oncol. 2017;35:142–3.

    Article  Google Scholar 

  35. Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, et al. A phase 2 study of rituximab-bendamustine and rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016;173(1):89–95.

    Article  CAS  PubMed  Google Scholar 

  36. Albertsson-Lindblad A, Kolstad A, Laurell A, Raty R, Gronbaek K, Sundberg J, et al. Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. Blood. 2016;128(14):1814–20.

    Article  CAS  PubMed  Google Scholar 

  37. Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944–53.

    Article  CAS  PubMed  Google Scholar 

  38. Till BG, Li H, Bernstein SH, Fisher RI, Burack R, Rimsza LM, et al. Phase II trial of R-CHOP plus Bortezomib induction therapy followed by bortezomib maintenance for previously untreated mantle cell lymphoma: SWOG 0601. Blood. 2014. American Society of Hematology;124(21):149.

    Article  Google Scholar 

  39. Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373(19):1835–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kruger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, et al. Allogeneic stem cell transplantation for mantle cell lymphoma – final report from the prospective trials of the east German Study Group Haematology/Oncology (OSHO). Ann Hematol. 2014;93(9):1587–97.

    Article  PubMed  Google Scholar 

  41. Tessoulin B, Ceballos P, Chevallier P, Blaise D, Tournilhac O, Gauthier J, et al. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplant. 2016;51(9):1184–90.

    Article  CAS  PubMed  Google Scholar 

  42. Saba NS, Liu D, Herman SE, Underbayev C, Tian X, Behrend D, et al. Pathogenic role of B-cell receptor signaling and canonical NF-kappaB activation in mantle cell lymphoma. Blood. 2016;128(1):82–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis. Leuk Res. 2013;37(10):1271–7.

    Article  CAS  PubMed  Google Scholar 

  44. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl BS, et al. Median 3.5-year follow-up of ibrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: a pooled analysis. Blood. 2017. American Society of Hematol;130(Suppl 1):151.

    Google Scholar 

  47. Stefoni V, Sottotetti F, Gotti M, Spina M, Volpetti S, Ferrero S, et al. Multicenter retrospective observational study to assess the clinical characteristics and the outcome of patients with relapsed or refractory mantle cell non-Hodgkin’s lymphoma treated in Italy according to the ibrutinib named patient program. Blood. 2016. American Society of Hematology;128(22):2985.

    Article  Google Scholar 

  48. Tucker DL, Naylor G, Kruger A, Hamilton MS, Follows G, Rule SA. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement – a multi-centre case series from the United Kingdom. Br J Haematol. 2017;178(2):327–9.

    Article  CAS  PubMed  Google Scholar 

  49. Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a “real world” study. Hematol Oncol. 2017;35(4):528–35.

    Article  CAS  PubMed  Google Scholar 

  50. Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175–9.

    Article  CAS  PubMed  Google Scholar 

  52. Kunk PR, Mock J, Devitt ME, Palkimas S, Sen J, Portell CA, et al. Major bleeding with ibrutinib: more than expected. Blood. 2016American Society of Hematology;128(22):3229.

    Article  Google Scholar 

  53. Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2017;391:659–67.

    Article  PubMed  Google Scholar 

  55. Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Tam CS, Simpson D, Opat S, Kim WS, Wang M, Cull G, et al. Safety and activity of the highly specific BTK inhibitor BGB-3111 in patients with indolent and aggressive non Hodgkin’s lymphoma. Blood. 2017. American Society of Hematology;130(Suppl 1):152.

    Google Scholar 

  57. Majchrzak A, Witkowska M, Smolewski P. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance. Molecules. 2014;19(9):14304–15.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822–9.

    Article  CAS  PubMed  Google Scholar 

  59. Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. 2011;12(4):361–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–8.

    Article  CAS  Google Scholar 

  61. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171(1):88–95.

    Article  CAS  PubMed  Google Scholar 

  62. Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Arcaini L, Lamy T, Walewski J, Belada D, Mayer J, Radford J, et al. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma. Br J Haematol. 2018;180(2):224–35.

    Article  CAS  PubMed  Google Scholar 

  64. Andorsky DJ, Yacoub A, Bitran JD, Melear J, Brooks HD, Foon KA, et al. MAGNIFY: phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by lenalidomide vs. rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone, or mantle cell lymphoma. Blood. 2016. American Society of Hematology;128(22):1798.

    Article  Google Scholar 

  65. Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10:171. https://doi.org/10.1186/s13045-017-0537-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, et al. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. Haematologica. 2017;102(5):e203–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20(3):520–5.

    Article  CAS  PubMed  Google Scholar 

  68. Furtado M, Johnson R, Kruger A, Turner D, Rule S. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015;168(1):55–62.

    Article  CAS  PubMed  Google Scholar 

  69. Dal Col J, Zancai P, Terrin L, Guidoboni M, Ponzoni M, Pavan A, et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood. 2008;111(10):5142–51.

    Article  CAS  PubMed  Google Scholar 

  70. Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, et al. A phase 1 study of the PI3K delta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123(22):3398–405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28(9):2169–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Tam CSL, Roberts AW, Anderson MA, Dawson S, Hicks RJ, Burbury K, et al. Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): primary endpoint assessment of the phase 2 AIM study. J Clin Oncol. 2017;35(15):7520.

    Article  Google Scholar 

  74. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119(20):4597–607.

    Article  CAS  PubMed  Google Scholar 

  75. Cassaday RD, Goy A, Advani S, Chawla P, Nachankar R, Gandhi M, et al. A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015;15(7):392–7.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Martin P, Blum K, Bartlett NL, Park SI, Maddocks KJ, Ruan J, et al. A phase I trial of ibrutinib plus palbociclib in patients with previously treated mantle cell lymphoma. Blood. 2016. American Society of Hematology;128(22):150.

    Article  Google Scholar 

  77. Seftel MD, Kuruvilla J, Kouroukis T, Banerji V, Fraser G, Crump M, et al. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A phase II study of the Canadian Cancer Trials Group. Leuk Lymphoma. 2017;58(6):1358–65.

    Article  CAS  PubMed  Google Scholar 

  78. Chen W, Du X, Luo C, Zhang Q, Wang M. Anti-CD19 chimeric antigen receptor T cells improve responses to chemotherapy-refractory mantle cell lymphoma: a case report. Blood. 2016. American Society of Hematology;128(22):5393.

    Article  Google Scholar 

  79. Abramson JS, Palomba L, Gordon LI, Lunning M, Arnason J, Forero-Torres A, et al. Transcend NHL 001: immunotherapy with the CD19-directed CAR T-cell product JCAR017 results in high complete response rates in relapsed or refractory B-cell non-Hodgkin lymphoma. Blood. 2016. American Society of Hematology;128(22):4192.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, USA

    Daniel R. Reed & Craig A. Portell

Authors
  1. Daniel R. Reed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Craig A. Portell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Craig A. Portell .

Editor information

Editors and Affiliations

  1. Department of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Christopher Dittus

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Reed, D.R., Portell, C.A. (2020). Mantle Cell Lymphoma. In: Dittus, C. (eds) Novel Therapeutics for Rare Lymphomas. Springer, Cham. https://doi.org/10.1007/978-3-030-25610-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25610-4_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25609-8

  • Online ISBN: 978-3-030-25610-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation